BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for BioNTech to acquire Kite’s solid tumor neoantigen T cell receptor (TCR) R&D platform and clinical manufacturing facility in Gaithersburg, MD. The acquired Gaithersburg facility will provide production capacity to support clinical trials in the United States and will complement BioNTech’s existing cell therapy manufacturing facility in Idar-Oberstein, Germany. The facility will support the development of BioNTech’s expanding pipeline of novel cell therapies, including cancer product candidates based on its CAR-T Cell amplifying mRNA vaccine (CARVac) and NEOSTIM platforms as well as the newly acquired individualized neoantigen TCR program.
Kite Seeking to Hire Cell Therapy Talent Ahead of Opening Its New Advanced Biomanufacturing Facility in Frederick, Maryland
A year and a half after announcing their plans to build a state-of-the-art cell manufacturing facility in Frederick County, Maryland, Kite, a Gilead Company, is looking to fill dozens of new biomanufacturing jobs in Maryland and add to the talented site team it already has in place.
Good News Stories of the Week – Featuring Donations, Facemasks, Tests and More. Governor Hogan Announces Acquisition of 500K Tests from South Korea Maryland’s Governor Larry Hogan announced this week [….]